http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
김윤준 대한간학회 2013 간학회 싱글토픽 심포지움 Vol.2013 No.2
Percutaneous ethanol injection therapy (PEIT), a potent non-surgical treatment tool for hepatocellular carcinoma (HCC), has been developed to manage small neoplasms. Intratumoral injection of only a few milliliters of ethanol with an ultrasonographic guidance allows PEIT to necrotize tumors completely and to reach reasonable survival rates comparable to radiofrequency ablation or liver resection. Advantages of PEIT include insignificant mortality, minimal damage to normal parenchyma, relatively low cost and easy availability; disadvantages include high local recurrence and minor complications such as fever and portal vein thrombosis. Recently with the introduction of single-session percutaneous ethanol injection, range of indications for PEIT is becoming wider. Furthermore, combined therapy of PEIT with transcatheter arterial chemoembolization (TACE) or other local ablation techniques is now being studied and performed with a satisfactory prospect.
김윤준 대한간학회 2013 임상연구방법론워크숍 Vol.2013 No.1
Case-control study is one of the retrospective studies, which is useful to find the cause or risk factor of disease. It could be performed easily, and cost effectively. The previous studies have found some meaningful relationship between use of nucleoside/tide analogue and post-operative recurrence in HBV-related HCC. However, most of them have some limitation, and more well-designed studies are needed in the future.